Pharmaceutical

Eisai lowers Leqembi revenue forecast after rocky entry to market

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

Nov 9, 2024 - 06:00
Eisai lowers Leqembi revenue forecast after rocky entry to market
Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.
Read the original article

Tags:

Previous Article

Ultra-processed food is causing a boom for obesity drug Ozempic

Next Article

Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

GSK’s Omjjara gains approval in Japan for myelofibrosis treatment

GSK’s Omjjara gains approval in Japan for myelofibrosis...

Jun 26, 2024

No pain data yet from Vertex, and sky high deal expectations at JPM 2024

No pain data yet from Vertex, and sky high deal expecta...

Jan 8, 2024

National panel dismisses calls for broader suicide risk screening

National panel dismisses calls for broader suicide risk...

Jun 20, 2023